Currently, the HER3-targeting antibody–drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) has demonstrated the most significant anticancer activity against several tumors, including EGFR-mutated NSCLC [175,176,177]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.